Navigation Links
Ruedi Waeger Receives the 2010 Robert W. Reilly Leadership Award from Plasma Protein Therapeutics Association
Date:6/25/2010

RESEARCH TRIANGLE PARK, N.C., June 25 /PRNewswire-FirstCall/ -- Ruedi Waeger, Ph.D., former president and CEO of Aventis Behring LLC and a member of the Talecris Board of Directors, was honored with the Robert W. Reilly Leadership award June 15 at the 2010 Plasma Protein Forum in Reston, VA.

The award is sponsored by the Plasma Protein Therapeutics Association (PPTA) and recognizes individuals who exemplify the leadership qualities of Robert Reilly, former leader of the PPTA. Reilly's efforts improved the quality of plasma products in the U.S. and enhanced the reputation of the plasma therapeutics industry worldwide.

Waeger was bestowed the award because of his significant contributions toward improving patient access to therapies, ensuring the highest quality and safety of plasma-derived products, and striving to achieve worldwide regulatory standardization of protein therapies.

"Ruedi's accomplishments throughout his 30-year career have contributed immensely to the field of protein therapeutics, and we are pleased that his accomplishments have been recognized by the industry," said Lawrence D. Stern, chairman and CEO of Talecris. "Ruedi's breadth of knowledge and experience continue to be tremendously valuable to Talecris, and we congratulate him on having received this honor from the PPTA."

Waeger has served on the Talecris Board since April 2005 and currently chairs the compliance committee. He also serves on the nominating and governance committees.  Waeger has more than 30 years of experience in the global pharmaceutical and therapeutic protein industries. Prior to joining the Talecris board, Waeger served as President and CEO of the plasma therapeutics company Aventis Behering LLC. Prior to that, he served as President and CEO of ZLB Central Laboratories and the Blood Transfusion Service of the Swiss Red Cross. Waeger earned a Ph.D. in biochemistry from the Swiss Federal Institute of Technology.

About the Robert W. Reilly Leadership Award

Robert Reilly was a leader in the plasma therapeutics industry association from 1992 to 1998. He created the first educational programs and industry symposia to confront the challenges facing the plasma industry worldwide. He also contributed significantly to the development of voluntary industry standards for quality plasma programs throughout the U.S., and his work helped open communications and build relationships with regulatory authorities and consumer groups.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com


'/>"/>
SOURCE Talecris Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
2. Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
3. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
4. Nile Therapeutics Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
5. Alexandria Real Estate Equities, Inc. Receives Final Approval From City of Cambridge to Develop Its East Cambridge State-of-the-Art Life Science Community
6. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
7. Fenwal Scientist Receives Research Award for Work on Photopheresis Therapy
8. China Sky One Medical Receives GMP Re-Certification
9. SyntheMed Receives CE Mark Approval for REPEL-GYN™
10. Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreichs Ataxia
11. Biomedical Structures Receives Growth Capital from Ampersand Ventures to Fund Ongoing Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016 Regen BioPharma Inc. (OTCQB: ... of Molecular Sciences a team of scientists in ... have demonstrated that expression of NR2F6 in patients with early ... NR2F6 in patient,s cervical cancer tissue as well as in ... "This is an interesting study and the first that I ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... website, http://www.autoreactors.com and online shopping cart. The new website has been ... functionality. These essential digital components allow customers to access detailed product information, read ...
(Date:12/6/2016)... , Dec. 6, 2016 The American Botanical ... adoption of arnica ( Arnica montana ) through ... ABC,s HerbMedPro database, a comprehensive, interactive ... and clinical research data on the uses and ... Naturopathica, a wellness company with healing ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Osteoarthritis Research Society International ... Administration (FDA) to consider OA as a serious disease. As an organization of ... population of OA patients, many of whom may experience progressive disability and decreased ...
Breaking Biology Technology:
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
Breaking Biology News(10 mins):